<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04717453</url>
  </required_header>
  <id_info>
    <org_study_id>DTX301-CL102</org_study_id>
    <nct_id>NCT04717453</nct_id>
  </id_info>
  <brief_title>Study to Characterize Rate of Ureagenesis in Patients With Ornithine Transcarbamylase (OTC) Deficiency</brief_title>
  <official_title>A Study to Characterize Rate of Ureagenesis Utilizing Oral [1-13C] Sodium Acetate in the Spectrum of Severity of Patients With Ornithine Transcarbamylase (OTC) Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ultragenyx Pharmaceutical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ultragenyx Pharmaceutical Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the study are to characterize urea production rates in patients with OTC,&#xD;
      characterize the association of rate of ureagenesis and disease severity in OTC patients,&#xD;
      characterize the association of rate of ureagenesis and executive and verbal function and&#xD;
      characterize the association of rate of ureagenesis and patient-reported functional status.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study DTX301-CL102 is a noninterventional, observational study to characterize the rate of&#xD;
      ureagenesis and to assess neurocognition and functional status in the spectrum of OTC&#xD;
      deficiency and their association with biochemical characteristics. [1-13C]Sodium acetate will&#xD;
      be administered orally as a tracer to measure the rate of ureagenesis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 6, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate over time of ureagenesis for 4 hours based on presence of [1-13C] in urea</measure>
    <time_frame>Predose (0hour) up to 4 hours post dose at Baseline, Weeks 24, 48, 72, and 96</time_frame>
    <description>Urea excretion after ingestion of sodium acetate as measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OTC Genotype</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>Genotype in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Hyperammonemic Crisis (HAC)</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive assessment</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>Cogstate platform</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hyperammonemia Indicator Questionnaire (HI-Q)</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>Patient-reported outcome (PRO) for symptoms of hyperammonemia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OTC Deficiency Impact Questionnaire (OTC-D-IQ)</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>PRO for impact of hyperammonemia</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ornithine Transcarbamylase Deficiency</condition>
  <arm_group>
    <arm_group_label>Adult Patients with OTC Deficiency</arm_group_label>
    <description>Eligible subjects will be asked to participate in 5 clinic visits, each lasting up to 3 days. Each visit will assess rate of ureagenesis during the 4 hours following ingestion of [1-13C]sodium acetate. Sodium acetate is used as a tracer to measure the rate of ureagenesis. Patient interview, reported outcomes and cognitive assessments will take place over the 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>No Intervention</description>
    <arm_group_label>Adult Patients with OTC Deficiency</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA for OTC genotype&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Approximately 30 patients will be enrolled, with up to 6 (20%) asymptomatic patients and at&#xD;
        least 18 (60%) patients with late-onset OTC deficiency.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide written informed consent.&#xD;
&#xD;
          -  For symptomatic patients:&#xD;
&#xD;
          -  Confirmed clinical diagnosis of OTC deficiency and enzymatic, biochemical, or&#xD;
             molecular testing.&#xD;
&#xD;
          -  Documented history of ≥ 1 symptomatic hyperammonemic episode with ammonia level ≥ 100&#xD;
             μmol/L&#xD;
&#xD;
          -  Patients on ongoing daily ammonia scavenger therapy must be at a stable dose(s) for ≥&#xD;
             4 weeks prior to Visit 1 (Baseline)&#xD;
&#xD;
          -  For asymptomatic patients: confirmed diagnosis of OTC deficiency by family history and&#xD;
             documented by molecular testing.&#xD;
&#xD;
          -  Willing and able to comply with the study procedures and requirements, including&#xD;
             clinic visits, blood and urine collections, questionnaires, and cognitive assessments.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Liver transplant, including hepatocyte cell therapy/transplant.&#xD;
&#xD;
          -  History of liver disease&#xD;
&#xD;
          -  Significant hepatic inflammation or cirrhosis&#xD;
&#xD;
          -  Participation in another investigational medicine study within 3 months of Screening&#xD;
&#xD;
          -  Participation (current or previous) in another gene transfer study&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
        Other protocol specific criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ultragenyx Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patients Contact: Trial Recruitment</last_name>
    <phone>1-888-756-8657</phone>
    <email>trialrecruitment@ultragenyx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>HCPs Contact: Medical Information</last_name>
    <phone>1-888-756-8657</phone>
    <email>medinfo@ultragenyx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Emerson Clinical Research Institute LLC</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PPD Phase 1 Clinic - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Trials Inc</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PPD Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OTC</keyword>
  <keyword>OTC Deficiency</keyword>
  <keyword>Neonatal</keyword>
  <keyword>Late Onset</keyword>
  <keyword>Asymptomatic Carrier</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ornithine Carbamoyltransferase Deficiency Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

